Integration of Personalized Medicine into the Management of Patients with Multiple Sclerosis


Program Dates: November 1st, 2019 - October 31st, 2020
Credits: 1.0 AMA PRA Category 1 Credit™


Integration of Personalized Medicine into the Management of Patients with Multiple Sclerosis

Program Overview

This CME program is derived from content presented at the Florida Society of Neurology 2019 Annual Meeting held in Orlando, Florida. The expert faculty will discuss the importance of personalized treatment strategies to more effectively care for patients with multiple sclerosis. This includes a review of current and emerging therapeutics for the treatment of highly active RRMS. The information provided by the expert faculty will enable healthcare providers to optimally treat and manage their patients with multiple sclerosis.

Target Audience

Neurologists, primary care physicians, PAs, NPs, and other healthcare providers involved in the management of patients with multiple sclerosis.

Learning Objectives

  1. Understand the importance of early diagnosis, disease classification, and personalized treatment strategies to more effectively treat patients with multiple sclerosis
  2. Analyze safety and efficacy data of current and emerging therapeutics for the treatment of highly active RRMS

Faculty

WM David Honeycutt, MD
Neurology Associates, PA
Maitland, FL
Co-Director of Florida Hospital Orlando Neuroscience Unit/SMART Unit
Editorial Board Florida Hospital Orlando Neuroscience Institute
Clinical Neurology Instructor, Florida Hospital Family Practice Program
Orlando, FL

 

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Relationship Identified With:
WM David Honeycutt, MD Consultant/Advisor: Biogen Pharmaceuticals, Sanofi-Genzyme, Genentech Inc., Roche, EMD Serono, Novartis Pharmaceuticals Corporation, Celgene Corporation

Speaker Bureau: Biogen Pharmaceuticals, Sanofi-Genzyme, Genentech Inc., Roche, EMD Serono, Novartis Pharmaceuticals Corporation, Celgene Corporation

Research/Grant Support: Actelion Pharmaceuticals, Adamas Pharmaceuticals, Alkermes, Medimmune

 

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Screen Shot 2018-12-11 at 12.19.42 PM

Credit Designation Statements

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Biogen Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Biogen Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact [email protected].

BUTTON

Provided by: AcademicCME-web